A novel integrated strategy (full length gene targeting) for mRNA accessible site tagging combined with microarray hybridization/RNase H cleavage to screen effective antisense oligonucleotides

Molecular Vision

Volumn 12, Issue , 2006, Pages 1364-1371

  Sun, Yuning ^a   Duan, Ming ^a   Lin, Ruxian ^a   Wang, Dan ^a   Li, Chunrong ^a   Bo, Xiaochen ^a   Wang, Shengqi ^a  

^a BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; MESSENGER RNA; PHOSPHORUS 32; RIBONUCLEASE H; SURVIVIN; URIDINE TRIPHOSPHATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER TRANSPLANTATION; COMPUTER PROGRAM; CONTROLLED STUDY; DISEASE MODEL; DOWN REGULATION; DRUG SCREENING; GENE FUNCTION; GENE LIBRARY; GENE TARGETING; GENE THERAPY; GENETIC ANALYSIS; GROWTH INHIBITION; LIVER CELL CARCINOMA; MICROARRAY ANALYSIS; MOLECULAR PROBE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RNA HYBRIDIZATION; TUMOR CELL;

ANIMALS; CARCINOMA, HEPATOCELLULAR; DOWN-REGULATION; GENE TARGETING; HUMANS; LIVER NEOPLASMS; MICE; MICE, NUDE; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OLIGONUCLEOTIDES, ANTISENSE; RIBONUCLEASE H, CALF THYMUS; RNA, MESSENGER; SEQUENCE TAGGED SITES; TUMOR CELLS, CULTURED;

EID: 33751520372     PISSN: 10900535     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Crooke ST. Molecular mechanisms of antisense drugs: RNase H. Antisense Nucleic Acid Drug Dev 1998; 8:133-4.
2. Wu H, Lima WF, Zhang H, Fan A, Sun H, Crooke ST. Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs. J Biol Chem 2004; 279:17181-9.
3. Galarneau A, Min KL, Mangos MM, Damha MJ. Assay for evaluating ribonuclease H-mediated degradation of RNA-antisense oligonucleotide duplexes. Methods Mol Biol 2005; 288:65-80.
4. Agrawal S, Zhao Q. Antisense therapeutics. Curr Opin Chem Biol 1998; 2:519-28.
5. Bennett CF, Cowsert LM. Application of antisense oligonucleotides for gene functionalization and target validation. Curr Opin Mol Ther 1999; 1:359-71.
6. Marshall J, Chen H, Yang D, Figueira M, Bouker KB, Ling Y, Lippman M, Frankel SR, Hayes DF. A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors. Ann Oncol 2004; 15:1274-83.
7. Roehr B. Fomivirsen approved for CMV retinitis. J Int Assoc Physicians AIDS Care 1998; 4:14-6.
8. McHutchison JG, Patel K, Pockros P, Nyberg L, Pianko S, Yu RZ, Dorr FA, Kwoh TJ. A phase I trial of an antisense inhibitor of hepatitis C virus (ISIS 14803), administered to chronic hepatitis C patients. J Hepatol 2006; 44:88-96.
9. Ball HA, Sandrasagra A, Tang L, Van Scott M, Wild J, Nyce JW. Clinical potential of respirable antisense oligonucleotides (RASONs) in asthma. Am J Pharmacogenomics 2003; 3:97-106.
10. Pirollo KF, Rait A, Sleer LS, Chang EH. Antisense therapeutics: from theory to clinical practice. Pharmacol Ther 2003; 99:55-77.
11. Pan WH, Clawson GA. Antisense applications for biological control. J Cell Biochem 2006; 98:14-35.
12. Ng EW, Shima DT, Calias P, Cunningham ET Jr, Guyer DR, Adamis AP. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 2006; 5:123-32.
13. Ng EW, Adamis AP. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can J Ophthalmol 2005; 40:352-68.
14. Stein CA. Keeping the biotechnology of antisense in context. Nat Biotechnol 1999; 17:209.
15. Sohail M, Southern EM. Selecting optimal antisense reagents. Adv Drug Deliv Rev 2000; 44:23-34.
16. Toulme JJ, Tinevez RL, Brossalina E. Targeting RNA structures by antisense oligonucleotides. Biochimie 1996; 78:663-73.
17. Milner N, Mir KU, Southern EM. Selecting effective antisense reagents on combinatorial oligonucleotide arrays. Nat Biotechnol 1997; 15:537-41.
18. Mir KU, Southern EM. Determining the influence of structure on hybridization using oligonucleotide arrays. Nat Biotechnol 1999; 17:788-92. Erratum in: Nat Biotechnol 1999; 17:1025.
19. Birikh KR, Berlin YA, Soreq H, Eckstein F. Probing accessible sites for ribozymes on human acetylcholinesterase RNA. RNA 1997; 3:429-37.
20. Lima WF, Brown-Driver V, Fox M, Hanecak R, Bruice TW. Combinatorial screening and rational optimization for hybridization to folded hepatitis C virus RNA of oligonucleotides with biological antisense activity. J Biol Chem 1997; 272:626-38.
21. Ho SP, Bao Y, Lesher T, Malhotra R, Ma LY, Fluharty SJ, Sakai RR. Mapping of RNA accessible sites for antisense experiments with oligonucleotide libraries. Nat Biotechnol 1998; 16:59-63.
22. Matveeva O, Felden B, Tsodikov A, Johnston J, Monia BP, Atkins JF, Gesteland RF, Freier SM. Prediction of antisense oligonucleotide efficacy by in vitro methods. Nat Biotechnol 1998; 16:1374-5.
23. Patzel V, Steidl U, Kronenwett R, Haas R, Sczakiel G. A theoretical approach to select effective antisense oligodeoxyribonucleotides at high statistical probability. Nucleic Acids Res 1999; 27:4328-34.
24. 't Hoen PA, Out R, Commandeur JN, Vermeulen NP, van Batenburg FH, Manoharan M, van Berkel TJ, Biessen EA, Bijsterbosch MK. Selection of antisense oligodeoxynucleotides against glutathione S-transferase Mu. RNA 2002; 8:1572-83.
25. Zhang HY, Mao J, Zhou D, Xu Y, Thonberg H, Liang Z, Wahlestedt C. mRNA accessible site tagging (MAST): a novel high throughput method for selecting effective antisense oligonucleotides. Nucleic Acids Res 2003; 31:e72.
26. Ito T, Shiraki K, Sugimoto K, Yamanaka T, Fujikawa K, Ito M, Takase K, Moriyama M, Kawano H, Hayashida M, Nakano T, Suzuki A. Survivin promotes cell proliferation in human hepatocellular carcinoma. Hepatology 2000; 31:1080-5.
27. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003; 3:46-54.
28. Morinaga S, Nakamura Y, Ishiwa N, Yoshikawa T, Noguchi Y, Yamamoto Y, Rino Y, Imada T, Takanashi Y, Akaike M, Sugimasa Y, Takemiya S. Expression of survivin mRNA associates with apoptosis, proliferation and histologically aggressive features in hepatocellular carcinoma. Oncol Rep 2004; 12:1189-94.
29. Olie RA, Simoes-Wust AP, Baumann B, Leech SH, Fabbro D, Stahel RA, Zangemeister-Wittke U. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res 2000; 60:2805-9.
30. Bo X, Wang S. TargetFinder: a software for antisense oligonucleotide target site selection based on MAST and secondary structures of target mRNA. Bioinformatics 2005; 21:1401-2.
31. Tu SP, Jiang XH, Lin MC, Cui JT, Yang Y, Lum CT, Zou B, Zhu YB, Jiang SH, Wong WM, Chan AO, Yuen MF, Lam SK, Kung HF, Wong BC. Suppression of survivin expression inhibits in vivo tumorigenicity and angiogenesis in gastric cancer. Cancer Res 2003; 63:7724-32.
32. Li F, Ackermann EJ, Bennett CF, Rothermel AL, Plescia J, Tognin S, Villa A, Marchisio PC, Altieri DC. Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat Cell Biol 1999; 1:461-6.
33. Chen J, Wu W, Tahir SK, Kroeger PE, Rosenberg SH, Cowsert LM, Bennett F, Krajewski S, Krajewska M, Welsh K, Reed JC, Ng SC. Down-regulation of survivin by antisense oligonucleotides increases apoptosis, inhibits cytokinesis and anchorageindependent growth. Neoplasia 2000; 2:235-41.
34. Cao C, Mu Y, Hallahan DE, Lu B. XIAP and survivin as therapeutic targets for radiation sensitization in preclinical models of lung cancer. Oncogene 2004; 23:7047-52. Erratum in: Oncogene. 2004; 23:9448.
35. Xia C, Xu Z, Yuan X, Uematsu K, You L, Li K, Li L, McCormick F, Jablons DM. Induction of apoptosis in mesothelioma cells by antisurvivin oligonucleotides. Mol Cancer Ther 2002; 1:687-94.
36. Lu B, Mu Y, Cao C, Zeng F, Schneider S, Tan J, Price J, Chen J, Freeman M, Hallahan DE. Survivin as a therapeutic target for radiation sensitization in lung cancer. Cancer Res 2004; 64:2840-5.
37. Ansell SM, Arendt BK, Grote DM, Jelinek DF, Novak AJ, Wellik LE, Remstein ED, Bennett CF, Fielding A. Inhibition of survivin expression suppresses the growth of aggressive non-Hodgkin's lymphoma. Leukemia 2004; 18:616-23.
38. Fraunfelder FW. Pegaptanib for wet macular degeneration. Drugs Today (Barc) 2005; 41:703-9.